TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE
TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE
Bone pain due to fibrous dysplasia of bone is usually treated with bisphosphonates. A small
 proportion of patients fail to respond adequately. Mutated bone cells produce large amounts
 of Interleukin-6 (IL-6), with increased bone resorption as a result. Inhibition of IL-6 may
 be of interest to reduce bone resorption and therefore bone pain. TOCIDYS is a
 placebo-controlled randomized cross-over trial to test the hypothesis that tocilizumab can
 reduce bone resorption in those patients with fibrous dysplasia who have already received
 bisphosphonates.
Inclusion Criteria:

 -  fibrous dysplasia of bone

 -  previously treated with IV bisphosphonates

 -  persistent bone pain and increased bone remodeling

 Exclusion Criteria:

 -  Chronic renal failure

 -  serious infectious diseases

 -  liver enzymes abnormality

 -  pregnancy

 -  dyslipidemia